Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies

Article ID	Journal	Published Year	Pages	File Type
6015403	Epilepsy Research	2015	10 Pages	PDF

Abstract

Hepatobiliary laboratory data and related TEAEs were not notably different between perampanel and placebo treatment groups, and no dose-related trends were observed. Based on the laboratory results from the 3 Phase III studies, perampanel (2, 4, 8, and 12Â mg) demonstrated no clinically important effects on liver function tests, indicating perampanel is an AED with a low potential for drug-induced liver toxicity.

Keywords

GGT NCI-CTC ULN ALT AED TEAE AST Aspartate aminotransferase Alanine aminotransferase Epilepsy Partial seizures Upper limit of normal antiepileptic drug antiepileptic drugs adverse event treatment-emergent adverse event Perampanel Liver Hepatic Gamma-glutamyl transferase